Pract 7 Valoracion de Aspirina

7/25/2019 Pract 7 Valoracion de Aspirina

http://slidepdf.com/reader/full/pract-7-valoracion-de-aspirina 1/3

PRACTICA 8.VALORACION DE UN PRODUCTO TERMINADO:

ASPIRINA(ACIDO ACETILSALICILICO)

LABORATORIO QUIMICA ANALITICA I.FARMACIA

Página 1 de 3

I Cuatrimestre 2016 Versión: 1

!"#$%$&'#" )"*+ ,$&- .$&'*#" /"012*' 3-

"#

$%&'()*++,-%.!" $%&'( )%*+&",)"&%-"&%( ( ../ 01234567 8%(9(%&'( :(:;")<=*9+* %(=( ),:&<&9)8

*, ;9 >$<=)%( '* ") >)=&"&) '* "(, ,)"&%&")+(,?

/* ;+&"&@) ><*%;*9+*=*9+* %(=( )9+&9>")=)+(<&( )9)"AB,&%( 0:)<) *" )"&C&( '*"

'("(< "*C* D =('*<)'(7 )9+&:&<B+&%( 0:)<) <*';%&< ") >&*E<*7 D )9+&)A<*A)9+*

:")F;*+)<&( 0&9'&%)'( :)<) :*<,(9), %(9 <&*,A( '* >(<=)%&G9 '* +<(=E(,

,)9A;-9*(,H :<&9%&:)"=*9+* &9'&C&';(, F;* I)9 +*9&'( ;9 &9>)<+( )A;'( '*

=&(%)<'&(7 0J;"&)9 KH 24 '5 L22M7?

N(, *>*%+(, )'C*<,(, '* ") ),:&<&9) ,(9 :<&9%&:)"=*9+* A),+<(&9+*,+&9)"*,H *,

'*%&<H O"%*<) :B:+&%),A$,+<&%), D ,)9A<)'( *,+(=)%)"? !9 :)%&*9+*, =*9(<*, '*

L6 )P(,H ") ),:&<&9) ,* I) '*Q)'( '* ;+&"&@)< :)<) <*';%&< ") >&*E<* 8*9 %),('* A<&:* ( '* C)<&%*")8 '*E&'( )" *"*C)'( <&*,A( '* %(9+<)*< *" ,-9'<(=* '* R*D*

0S)%'(9)"'H TUUT7?

V&A;<) L? S("B%;") '* $%&'( )%*+&",)"&%-"&%( ../

. "), '(,&, I)E&+;)"*,H "(, *>*%+(, )'C*<,(, =$, %(=;9*, '* ") ),:&<&9) ,(9

") &<<&+)%&G9 A$,+<&%)H 9$;,*),H CG=&+(,H O"%*<) A$,+<&%) ( ';('*9)" 0S*'"&9*H

TUUW7H =&*9+<), F;* ") I*:)+(+(X&%&')'H ),=)H %)=E&(, *9 ")

:&*" D 9*><(+(X&%&')' ,(9 =*9(, ><*%;*9+*,? /* I) <*:(<+)'( F;* (%;<<*

)'):+)%&G9 '* ") =;%(,) *9 :)%&*9+*, %(9 O"%*<), ),(%&)'), ) ") )'=&9&,+<)%&G9

'* ),:&<&9) '* =('( F;* ,* I) '*=(,+<)'( *" =*Q(<)=&*9+( *,:(9+$9*( %(9 *"

+&*=:( ,&9 '*,%(9+&9;)< ") +(=) '* ") ),:&<&9)?

/# 01&2',1324 5 67*,8( 98(' 27*,8( )2 &'1:1;(<

T?L !<"*9=*D*< '* TYU=N 067

T?L Z;<*+) '* YU =" 0L7

=# >21+&,?(4[?L \)E"*+), '* ),:&<&9)

[?T ])53 U?L ]

[?[ 31" U?L]

[?6 V*9(">+)"*-9) ,(";%&G9 &9'&%)'(<)






Página 2 de 3


@# A:;2&,?(46?LK*+*<=&9)< *" :(<%*9+)Q* '* ),:&<&9) *9 ") =;*,+<)

6?T ^<)%+&%)< ") +B%9&%) '* C)"(<)%&G9 :(< <*+<(%*,(

6?[ _+&"&@)< ") *,+)'-,+&%) :)<) <*:(<+)< "(, <*,;"+)'(,

B# C'(+2),D,2%&(C'281'1+,-% )2 31 D*24&'14 5 ?13('1+,-%Y?L K*+*<=&9)< *" :*,( :<(=*'&( '* "), +)E"*+) ) :)<+&< '* TU +)E"*+),

Y?T S(<+*<&@)< >&9)=*9+* "), TU +)E"*+),

Y?[ ^(< +<&:"&%)'( +<)9,>&*<) UHM A '* :("C( =(<+*<&@)'(H "( =$, *X)%+)=*9+*

=*'&'(, D +<)9,>&B<)"(, ) ;9 *<"*9=*D*< '* TYU=N?

Y?6 .'&%&(9* TU =" '* )"%(I(" 9*;+<)"&@)'( D *9><&)'( *9+<* LY D TU `1?

Y?Y .A&+)< I),+) '&,("C*< 0 9( ,* '&,;*"C* +('(7?Y?M a)"(<* %(9 ])53 U?L ] %(9 &9'&%)'(< '* >*9(">+)"*-9)H I),+) ") ):)<&%&G9

'*" :<&=*< +(9( <(,)'( F;* ,* =)9+*9A) :(< [U ,*A;9'(,?

Y?W .A<*A;* %(9 ") E;<*+) ;9 C(";=*9 &A;)" '* ])53 )" %(9,;=&'( =), Y ="

=), 09 b Y7

Y?4 1)"*9+)< *9 E)P( S)<&) ';<)9+* LY =&9;+(,H 9( :),)< '* 6U `1H )A&+)<

><*%;*9+*=*9+*?

Y?2 !9><&)< ) +*=:*<)+;<) )=E&*9+*

Y?LU a)"(<)< *" *X%*,( '* ])53 U?L ] %(9 31" U?L ]?

Y?LL K*+*<=&9)< ") %)9+&')' '* ),:&<&9) :<*,*9+* *9 ") =;*,+<) D *X:<B,*"(

%(=( :(<%*9+)Q*?

1;)'<( L? K)+(, *X:*<&=*9+)"*, '* C)"(<)%&G9 :<(=*'&( '* $%&'( ,)"&%-"&%(

=)+*<&) :<&=)

DE FG3,%,+,1324

DE FG3H,%1324

DE &(&1324 I J48,',%1DKD

0*24&'1 "

0*24&'1 /

0*24&'1 =

I J48,',%1

8'(D2),(4

GL

M# GN3+*3(4

" J48,',%1# 00ac1(9%7 ])53 09bY7 d 00ac1(9%731"7cL4U?LMc:*,( :<(=cLUU

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

=),) =;*,+<) 0=A7cYUU






Página 3 de 3


%&'()*+'.

,)-.+/0+12 )-342*/& .

6482+,H,+1+,-%. !" %(9+*9&'( '* ),:&<&9) :(< +)E"*+) '*E* *,+)< *9+<* 2U e D LLU

e '* ") %)9+&')' *+&F;*+)')

O# G*24&,(%1',()?

1;)" *, *" <)9A( '* :3 '* C)<&)%&G9 '*" &9'&%)'(< ;+&"&@)'(f

E? ^(< F;* ,* C)"(<) *" *X%*,( '* ])53 U?L] %(9 31" U?L ]f

ZgZNg5hR.Vg.

1. Julian, D G; D A Chamberlain, S J Pocock (24 de septiembre de 1996). «A comparison of

aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER

study): a multicentre unblinded randomised clinical trial». BMJ (British Medical

Journal) 313 (7070): 1429–1431.PMID 8973228. Consultado el 4 de octubre de 2007.

2. Macdonald S (2002). «Aspirin use to be banned in under 16 year olds». BMJ 325 (7371):

988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585.PMID

3. por MedlinePlus (enero de 2007). «Aspirina». Enciclopedia médica en español .

Consultado el 7 de novimebre de 2008.

Pract 7 Valoracion de Aspirina

Documents

Transcript of Pract 7 Valoracion de Aspirina